BioAlliance, EMS deal

BioAlliance granted EMS rights to commercialize Sitavig acyclovir Lauriad in Brazil. The mucoadhesive formulation of acyclovir is approved in the U.S. and Europe for recurrent orofacial herpes. EMS will seek regulatory approval in Brazil. BioAlliance will receive an undisclosed transfer payment and will be eligible for regulatory milestone payments. The companies could not be reached for details. ...